Conflict of Interest: Nothing to declare.
Article first published online: 25 OCT 2012
Copyright © 2012 Wiley Periodicals, Inc.
Pediatric Blood & Cancer
Supplement: Congenital and Acquired Pediatric Bleeding Disorders: Reports from the Toronto 2011 Symposium
Volume 60, Issue Supplement 1, pages S30–S33, 2013
How to Cite
DiMichele, D. M. (2013), Inhibitors in childhood hemophilia A: Genetic and treatment-related risk factors for development and eradication. Pediatr. Blood Cancer, 60: S30–S33. doi: 10.1002/pbc.24338
Wiley has published this supplement with financial support from the Hospital for Sick Children in Toronto [non-commercial entity].
- Issue published online: 15 NOV 2012
- Article first published online: 25 OCT 2012
- Manuscript Received: 30 AUG 2012
- Manuscript Accepted: 30 AUG 2012
- hemophilia A;
- genetic risk factors;
The development of neutralizing antibodies remains a serious complication of hemophilia replacement therapy. Factor VIII inhibiting antibodies (inhibitors) occur commonly following replacement therapy in hemophilia A, creating a significant burden of clinical disease. This article will review our current understanding of risk factors and their known impact on inhibitor development in previously untreated or minimally treated children with severe and mild hemophilia A. It will also explore how the most recently elucidated immunology of inhibitor development might hold important clues to more effective inhibitor eradication and prevention in this heavily impacted patient population. Pediatr Blood Cancer 2012; 60: S30–S33. © 2012 Wiley Periodicals, Inc.